PDF(Pubmed)
Abstract：
BACKGROUND: Many factors contribute to quality of life (QoL) in patients with schizophrenia, yet limited research examined these factors in patients in China. This cross-sectional study explores subjective QoL and its associated factors in patients.
METHODS: The QoL was assessed using the Schizophrenia Quality of Life Scale (SQLS). Clinical symptoms were evaluated using the Brief Psychiatric Rating Scale (BPRS) and seven factors were extracted. Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder Scale (GAD-7) were used to assess depression and anxiety. Cognitive impairment was assessed using the Ascertain Dementia 8 (AD8). The Treatment Emergent Symptom Scale (TESS) and Rating Scale for Extrapyramidal Side Effects (RSESE) were used to evaluate the side effects of medications.
RESULTS: We recruited 270 patients (male:142,52.6%, mean age:41.9 ± 9.4 years). Positive correlations were observed between SQLS and its subdomains with the total score of BPRS, PHQ-9, GAD-7, AD8, TESS, and RSESE (all P < 0.005). Patients who were taking activating second-generation antipsychotics (SGAs) had lower scores on total SQLS, Motivation/ Energy domain of SQLS (SQLS-ME) as well as Symptoms/ Side effects domain of SQLS (SQLS-SS) compared to those taking non-activating SGAs (all P < 0.005). Multiple regression analysis showed that depressive/ anxiety symptoms and cognitive impairment had significant negative effects on QoL (P ≤ 0.001), while activating SGAs had a positive effect (P < 0.005). Blunted affect and unemployment were inversely associated with the motivation/energy domain (P < 0.001).
CONCLUSIONS: Our findings emphasize the important role of depression/anxiety symptoms and cognitive impairment in the QoL of patients with chronic schizophrenia. Activating SGAs and employment may improve the QoL of these individuals.
BACKGROUND: This protocol was registered at chictr.org.cn (Identifier: ChiCTR2100043537).
METHODS: The QoL was assessed using the Schizophrenia Quality of Life Scale (SQLS). Clinical symptoms were evaluated using the Brief Psychiatric Rating Scale (BPRS) and seven factors were extracted. Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder Scale (GAD-7) were used to assess depression and anxiety. Cognitive impairment was assessed using the Ascertain Dementia 8 (AD8). The Treatment Emergent Symptom Scale (TESS) and Rating Scale for Extrapyramidal Side Effects (RSESE) were used to evaluate the side effects of medications.
RESULTS: We recruited 270 patients (male:142,52.6%, mean age:41.9 ± 9.4 years). Positive correlations were observed between SQLS and its subdomains with the total score of BPRS, PHQ-9, GAD-7, AD8, TESS, and RSESE (all P < 0.005). Patients who were taking activating second-generation antipsychotics (SGAs) had lower scores on total SQLS, Motivation/ Energy domain of SQLS (SQLS-ME) as well as Symptoms/ Side effects domain of SQLS (SQLS-SS) compared to those taking non-activating SGAs (all P < 0.005). Multiple regression analysis showed that depressive/ anxiety symptoms and cognitive impairment had significant negative effects on QoL (P ≤ 0.001), while activating SGAs had a positive effect (P < 0.005). Blunted affect and unemployment were inversely associated with the motivation/energy domain (P < 0.001).
CONCLUSIONS: Our findings emphasize the important role of depression/anxiety symptoms and cognitive impairment in the QoL of patients with chronic schizophrenia. Activating SGAs and employment may improve the QoL of these individuals.
BACKGROUND: This protocol was registered at chictr.org.cn (Identifier: ChiCTR2100043537).
摘要：
背景：许多因素有助于精神分裂症患者的生活质量（QoL），然而，有限的研究研究了中国患者的这些因素。这项横断面研究探讨了患者的主观QoL及其相关因素。
方法：使用精神分裂症生活质量量表（SQLS）评估QoL。使用简明精神病评定量表（BPRS）评估临床症状，并提取七个因素。患者健康问卷-9（PHQ-9），采用广义焦虑症量表(GAD-7)评估抑郁和焦虑情绪。使用AscertainDementia8（AD8）评估认知障碍。使用治疗主要症状量表（TESS）和锥体外系副作用量表（RSESE）评估药物的副作用。
结果：我们招募了270名患者（男性：142,52.6％，平均年龄：41.9±9.4岁）。SQLS及其子域与BPRS总分呈正相关，PHQ-9,GAD-7,AD8,TESS,和RSESE（所有P<0.005）。服用激活第二代抗精神病药（SGAs）的患者在总SQLS上得分较低，与服用非激活SGA的人相比，SQLS的动机/能量域（SQLS-ME）以及SQLS的症状/副作用域（SQLS-SS）（所有P<0.005）。多元回归分析显示,抑郁/焦虑症状和认知障碍对QoL有显著的负面影响(P≤0.001),而激活SGAs有积极作用(P<0.005)。钝性情感和失业与动机/能量域呈负相关(P<0.001)。
结论：我们的研究结果强调了抑郁/焦虑症状和认知障碍在慢性精神分裂症患者QoL中的重要作用。激活SGA和就业可能会改善这些人的QoL。
背景：此协议已在chictr.org注册。cn(标识符:ChiCTR2100043537)。
方法：使用精神分裂症生活质量量表（SQLS）评估QoL。使用简明精神病评定量表（BPRS）评估临床症状，并提取七个因素。患者健康问卷-9（PHQ-9），采用广义焦虑症量表(GAD-7)评估抑郁和焦虑情绪。使用AscertainDementia8（AD8）评估认知障碍。使用治疗主要症状量表（TESS）和锥体外系副作用量表（RSESE）评估药物的副作用。
结果：我们招募了270名患者（男性：142,52.6％，平均年龄：41.9±9.4岁）。SQLS及其子域与BPRS总分呈正相关，PHQ-9,GAD-7,AD8,TESS,和RSESE（所有P<0.005）。服用激活第二代抗精神病药（SGAs）的患者在总SQLS上得分较低，与服用非激活SGA的人相比，SQLS的动机/能量域（SQLS-ME）以及SQLS的症状/副作用域（SQLS-SS）（所有P<0.005）。多元回归分析显示,抑郁/焦虑症状和认知障碍对QoL有显著的负面影响(P≤0.001),而激活SGAs有积极作用(P<0.005)。钝性情感和失业与动机/能量域呈负相关(P<0.001)。
结论：我们的研究结果强调了抑郁/焦虑症状和认知障碍在慢性精神分裂症患者QoL中的重要作用。激活SGA和就业可能会改善这些人的QoL。
背景：此协议已在chictr.org注册。cn(标识符:ChiCTR2100043537)。
